Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Clinical trial NCT05786040 · RECRUITING

Trial details

NCT number: NCT05786040
Sponsor: Timothy Voorhees
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder Polymorphic Post-Transplant Lymphoproliferative Disorder

Start date: 2023-03-23
Primary completion: 2027-12-31
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.